Stimulation of Angiotensin Converting Enzyme 2: A Novel Treatment Strategy for Diabetic Nephropathy

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetic nephropathy often progresses to end-stage renal disease despite existing therapies.
• Chronic activation of the renin-angiotensin-aldosterone system (RAAS) is a key factor in diabetic nephropathy pathogenesis.
• Current treatments include ACE inhibitors and Ang II receptor blockers, but further options are needed.

Purpose of the Study:

• To review the role of the reno-protective arm of the RAAS in diabetic nephropathy.
• To explore how targeting angiotensin converting enzyme 2 (ACE2) can ameliorate kidney damage.
• To evaluate ACE2 stimulation as a therapeutic strategy for diabetic nephropathy.

Main Methods:

• Review of existing literature on RAAS, ACE2, and diabetic nephropathy.
• Analysis of the mechanisms by which ACE2 exerts reno-protective effects.
• Examination of therapeutic potential of targeting the ACE2/Ang 1-7 axis.

Main Results:

• Angiotensin converting enzyme 2 (ACE2) converts Angiotensin II to Angiotensin 1-7, which has reno-protective effects.
• Chronic RAAS activation contributes to kidney inflammation and fibrosis.
• Targeting the ACE2 pathway offers a promising approach to counteract these effects.

Conclusions:

• Stimulating tissue ACE2 presents a unique and promising therapeutic strategy for diabetic nephropathy.
• Targeting the reno-protective RAAS arm could offer novel treatments for kidney fibrosis and inflammation.
• Further research into ACE2 stimulation may lead to improved outcomes for patients with diabetic nephropathy.